Clinical Trial Search

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients…

Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale

Primary: Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. — -56 percentage change from baseline

Primary: Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants — 3; 2; 9; 2 participants

Primary: Number of Participants Who Had a Prostate-specific Antigen (PSA) Response — 52 Participants

Primary: Mean Prostate Specific Antigen (PSA) Level — 0.61; 0.70; 0.54 ng/mL

Primary: Percentage of Patients Who Achieve an Undetectable PSA (=< 0.2 ng/ml) — 0.0 percentage of patients

Primary: Overall Response Rate (ORR) — 50 percentage of participants

Primary: Change in Tissue Testosterone and Dihydrotestosterone — 0.156 pg/mg

Primary: Changes in 18F-fluciclovine PET Scan for Patients With mCRPC on Treatment With Life Prolonging Therapies — 5; 0; 3; 0 Participants

Primary: Proportion of Patients With PSA Decline by 50% From Baseline — 9; 5 Participants

Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 Given Every Two Weeks. — 20 mg/kg every 2 weeks

Primary: Recommended Phase 2 Dose (RP2D) — 25 mg

Primary: Clinical Benefit Rate From Cabozantinib (XL184) — 10 Participants

Primary: Percentage of Participants With PSA50 Response — 2 Participants

Primary: Number of Reported Dose Limiting Toxicities (DLT) (Part A Only) — 0; 1; 1 dose-limiting toxicities

Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants

Primary: Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR]) — 6.8 percentage of participants

Primary: Undetectable PSA Rate — 42; 34 participants — p=0.16

Primary: Efficacy as Assessed by 3-year Prostate-specific Antigen Progression-free Survival Rate — 22; 3 Participants

Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…

Primary: Percentage of Patients Who Complete the Pre/Post Exercise Intervention Testing. — 16 Participants

Primary: Gallium Ga 68-DOTATATE Uptake — 11; 4; 1 Participants

Primary: Time to Progression — 11.2 weeks

Primary: Metabolic Syndrome — 0; 0 kilograms

Primary: Percent Probability of Participants With 6-month Progression-free Survival (PFS) — 43.9 percent probability

Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151

Primary: Biochemical Response Rate — 0 participants